» Articles » PMID: 32995423

Potential Depressive Central Nervous System Effects of Brimonidine Topical Gel

Overview
Journal JAAD Case Rep
Specialty Dermatology
Date 2020 Sep 30
PMID 32995423
Authors
Affiliations
Soon will be listed here.
References
1.
Haber R, El Gemayel M . Comorbidities in rosacea: A systematic review and update. J Am Acad Dermatol. 2017; 78(4):786-792.e8. DOI: 10.1016/j.jaad.2017.09.016. View

2.
Lipner S . Novel Use of Brimonidine 0.33% Gel for Hemostasis in Nail Surgery. Dermatol Surg. 2018; 45(7):993-996. DOI: 10.1097/DSS.0000000000001632. View

3.
Meana J, Barturen F, Garcia-Sevilla J . Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry. 1992; 31(5):471-90. DOI: 10.1016/0006-3223(92)90259-3. View

4.
Shagalov D, Taylor D, Schleichert R, Weiss J, Weiss E . Association of Central Nervous System Depression With Topical Brimonidine When Used for Hemostasis: A Serious Adverse Event. JAMA Dermatol. 2017; 153(6):575-577. PMC: 5817602. DOI: 10.1001/jamadermatol.2017.0247. View

5.
Docherty J, Steinhoff M, Lorton D, Detmar M, Schafer G, Holmes A . Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy. Adv Ther. 2016; 33(11):1885-1895. PMC: 5083782. DOI: 10.1007/s12325-016-0404-8. View